Literature DB >> 31911545

Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy.

Feng Xie1,2, Jianjun Zhang3,4, Jiayin Wang5, Alexandre Reuben6, Wei Xu2, Xin Yi7, Frederick S Varn8, Yongsheng Ye2, Junwen Cheng2, Miao Yu2, Yue Wang2, Yufeng Liu2, Mingchao Xie2, Peng Du2, Ke Ma2, Xin Ma5, Penghui Zhou9, Shengli Yang10, Yaobing Chen1,11, Guoping Wang2,11, Xuefeng Xia12, Zhongxing Liao13, John V Heymach6, Ignacio I Wistuba14, P Andrew Futreal4, Kai Ye15,16, Chao Cheng17,18, Tian Xia19,2,11.   

Abstract

PURPOSE: Tumor genomic features have been of particular interest because of their potential impact on the tumor immune microenvironment and response to immunotherapy. Due to the substantial heterogeneity, an integrative approach incorporating diverse molecular features is needed to characterize immunologic features underlying primary resistance to immunotherapy and for the establishment of novel predictive biomarkers. EXPERIMENTAL
DESIGN: We developed a pan-cancer deep machine learning model integrating tumor mutation burden, microsatellite instability, and somatic copy-number alterations to classify tumors of different types into different genomic clusters, and assessed the immune microenvironment in each genomic cluster and the association of each genomic cluster with response to immunotherapy.
RESULTS: Our model grouped 8,646 tumors of 29 cancer types from The Cancer Genome Atlas into four genomic clusters. Analysis of RNA-sequencing data revealed distinct immune microenvironment in tumors of each genomic class. Furthermore, applying this model to tumors from two melanoma immunotherapy clinical cohorts demonstrated that patients with melanoma of different genomic classes achieved different benefit from immunotherapy. Interestingly, tumors in cluster 4 demonstrated a cold immune microenvironment and lack of benefit from immunotherapy despite high microsatellite instability burden.
CONCLUSIONS: Our study provides a proof for principle that deep learning modeling may have the potential to discover intrinsic statistical cross-modality correlations of multifactorial input data to dissect the molecular mechanisms underlying primary resistance to immunotherapy, which likely involves multiple factors from both the tumor and host at different molecular levels. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 31911545      PMCID: PMC7299824          DOI: 10.1158/1078-0432.CCR-19-1744

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  51 in total

1.  Reducing the dimensionality of data with neural networks.

Authors:  G E Hinton; R R Salakhutdinov
Journal:  Science       Date:  2006-07-28       Impact factor: 47.728

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

5.  Integrative Data Analysis of Multi-Platform Cancer Data with a Multimodal Deep Learning Approach.

Authors:  Muxuan Liang; Zhizhong Li; Ting Chen; Jianyang Zeng
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2015 Jul-Aug       Impact factor: 3.710

6.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.

Authors:  Teresa Davoli; Hajime Uno; Eric C Wooten; Stephen J Elledge
Journal:  Science       Date:  2017-01-20       Impact factor: 47.728

Review 7.  The NCI Genomic Data Commons as an engine for precision medicine.

Authors:  Mark A Jensen; Vincent Ferretti; Robert L Grossman; Louis M Staudt
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 9.  Deep learning: new computational modelling techniques for genomics.

Authors:  Gökcen Eraslan; Žiga Avsec; Julien Gagneur; Fabian J Theis
Journal:  Nat Rev Genet       Date:  2019-07       Impact factor: 53.242

10.  RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease.

Authors:  Hui Y Xiong; Babak Alipanahi; Leo J Lee; Hannes Bretschneider; Daniele Merico; Ryan K C Yuen; Yimin Hua; Serge Gueroussov; Hamed S Najafabadi; Timothy R Hughes; Quaid Morris; Yoseph Barash; Adrian R Krainer; Nebojsa Jojic; Stephen W Scherer; Benjamin J Blencowe; Brendan J Frey
Journal:  Science       Date:  2014-12-18       Impact factor: 47.728

View more
  9 in total

1.  Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors.

Authors:  Xiangxue Wang; Cristian Barrera; Kaustav Bera; Vidya Sankar Viswanathan; Sepideh Azarianpour-Esfahani; Can Koyuncu; Priya Velu; Michael D Feldman; Michael Yang; Pingfu Fu; Kurt A Schalper; Haider Mahdi; Cheng Lu; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Sci Adv       Date:  2022-06-01       Impact factor: 14.957

2.  Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Authors:  Chuanzhi Chen; Yi Chen; Xin Jin; Yongfeng Ding; Junjie Jiang; Haohao Wang; Yan Yang; Wu Lin; Xiangliu Chen; Yingying Huang; Lisong Teng
Journal:  Front Mol Biosci       Date:  2022-04-11

Review 3.  Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.

Authors:  Florian Huemer; Michael Leisch; Roland Geisberger; Thomas Melchardt; Gabriel Rinnerthaler; Nadja Zaborsky; Richard Greil
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

4.  Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.

Authors:  Ming Chen; Runzhe Chen; Ying Jin; Jun Li; Xin Hu; Jiexin Zhang; Junya Fujimoto; Shawna M Hubert; Carl M Gay; Bo Zhu; Yanhua Tian; Nicholas McGranahan; Won-Chul Lee; Julie George; Xiao Hu; Yamei Chen; Meijuan Wu; Carmen Behrens; Chi-Wan Chow; Hoa H N Pham; Junya Fukuoka; Jia Wu; Edwin Roger Parra; Latasha D Little; Curtis Gumbs; Xingzhi Song; Chang-Jiun Wu; Lixia Diao; Qi Wang; Robert Cardnell; Jianhua Zhang; Jing Wang; Xiuning Le; Don L Gibbons; John V Heymach; J Jack Lee; William N William; Chao Cheng; Bonnie Glisson; Ignacio Wistuba; P Andrew Futreal; Roman K Thomas; Alexandre Reuben; Lauren A Byers; Jianjun Zhang
Journal:  Nat Commun       Date:  2021-11-17       Impact factor: 17.694

Review 5.  Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.

Authors:  Laurent Dercle; Jeremy McGale; Shawn Sun; Aurelien Marabelle; Randy Yeh; Eric Deutsch; Fatima-Zohra Mokrane; Michael Farwell; Samy Ammari; Heiko Schoder; Binsheng Zhao; Lawrence H Schwartz
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

6.  Comprehensive analysis of PTPN gene family revealing PTPN7 as a novel biomarker for immuno-hot tumors in breast cancer.

Authors:  Fengxu Wang; Xuehai Wang; Lei Liu; Siyuan Deng; Wenqian Ji; Yang Liu; Xiangdong Wang; Rui Wang; Xinyuan Zhao; Erli Gao
Journal:  Front Genet       Date:  2022-09-26       Impact factor: 4.772

7.  Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes.

Authors:  Zicheng Zhang; Congcong Yan; Ke Li; Siqi Bao; Lei Li; Lu Chen; Jingting Zhao; Jie Sun; Meng Zhou
Journal:  NPJ Genom Med       Date:  2021-06-17       Impact factor: 8.617

Review 8.  Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy.

Authors:  Laura Bracci; Alessandra Fragale; Lucia Gabriele; Federica Moschella
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

9.  Random survival forest model identifies novel biomarkers of event-free survival in high-risk pediatric acute lymphoblastic leukemia.

Authors:  Zachary S Bohannan; Frederick Coffman; Antonina Mitrofanova
Journal:  Comput Struct Biotechnol J       Date:  2022-01-06       Impact factor: 6.155

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.